Defining Trajectories of Response in Psoriasis Patients Treated with Biologic Therapies
Br J Dermatol, 2021.
Geifman N, Azadbakht N, Zeng J, Wilkinson T, Dand N, Buchan I, Stocken D, Di Meglio P, Warren RB, Barker JN; Reynolds NJ, Barnes MR, Smith CH, Griffiths CEM, Peek N; BADBIR Study Group, on behalf of the PSORT Consortium.
Read publication: Br J Dermatol 2021
Related
Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study...
Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic ...
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective c...
0 Comments